Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
OBJECTIVE
We determined the clinical efficacy and safety of terazosin in the treatment of patients with female lower urinary tract symptoms.


METHODS
A total of 100 females 20 to 70 years old who met the inclusion criteria of total International Prostate Symptom Score 8 or greater, symptom duration 1 or more months, and did not meet any exclusion criteria were entered into the study. Subjects were randomized to receive terazosin or placebo in titrated dose from 1 mg od, 1 mg twice daily to 2 mg twice daily during 14 weeks. Successful treatment outcomes use primary end point of International Prostate Symptom Score quality of life 2 or less and secondary end point of total International Prostate Symptom Score 7 or less. Other outcome measures included International Prostate Symptom Score individual item scores, King's Health Questionnaire quality of life domains, objective assessment parameters of 24-hour frequency volume chart, maximum flow rate and post-void residual urine.


RESULTS
Using a primary end point, 32 of 40 (80%) evaluable terazosin subjects responded in contrast to 22 of 40 (55%) evaluable placebo subjects (p <0.02). The secondary end point revealed a successful outcome in 85% of terazosin subjects vs 55% in placebo (p <0.01). Of the 7 International Prostate Symptom Score individual item scores, only item scores of frequency and straining showed statistically significant reductions with terazosin (p <0.01). All King's Health Questionnaire quality of life domains except domain of severity measures showed statistically significant improvement with terazosin (p <0.05). There were no differences between treatment groups in all objective assessment parameters. Of all evaluable subjects 23 of 40 (58%) on placebo experienced adverse events vs 16 of 40 (40%) on terazosin (p >0.05).


CONCLUSIONS
Terazosin proved to be more effective and safe than placebo in patients with female lower urinary tract symptoms.
Low
Bee Yean
BY
School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia.
Liong
Men Long
ML
Yuen
Kah Hay
KH
Chee
Christopher
C
Leong
Wing Seng
WS
Chong
Wooi Loong
WL
Khan
Nurzalina Abdul Karim
NA
Cheah
Phaik Yeong
PY
Liong
Ker Keong
KK
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014555:Urination Disorders / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin